Linked Life Data

15768380

Source:http://linkedlifedata.com/resource/pubmed/id/15768380

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-11-22
pubmed:abstractText
The objectives of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1545-5009
pubmed:author
pubmed:issnType
Print
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
50-5
pubmed:dateRevised
2009-1-12
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
A phase I study of irinotecan administered on a weekly schedule in pediatric patients.
pubmed:affiliation
Texas Children's Cancer Center/Baylor College of Medicine, Houston, TX 77030, USA. lbomgaars@txccc.org
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase I, Research Support, N.I.H., Extramural